Breast Cancer

, Volume 26, Issue 4, pp 485–491 | Cite as

URG4 expression in invasive breast carcinoma and its relation to clinicopathological characteristics

  • Figen AslanEmail author
  • Ayla Solmaz Avcıkurt
Original Article



Upregulated gene 4 (URG4) is a recently described oncogene that upregulates cell proliferation. Its overexpression has been identified in many malignancies, and it is thought to be related to tumour progression, angiogenesis, metastasis and the recurrence of many cancers. This is the first study to show its expression in breast cancer patients and its association with clinicopathological characteristics in these patients.


Fifty invasive ductal breast carcinoma cases and 25 control cases were included in the study. Tumourous tissues and control tissues were assessed molecularly for quantification of mRNA expression of URG4 and immunohistochemically for protein expression of URG4.


The mean ages of the patients and controls were 54.3 ± 11.3 and 38.9 ± 9.7 years, respectively. The expression levels of URG4 mRNA in tumour tissues were higher compared to control breast tissues (p = 0.023). An immunohistochemical assessment suggested that URG4 is strongly expressed in normal breast tissues and lower-grade (grades I and II) ductal carcinomas of the breast, but it is weakly expressed in high-grade (grade III) ductal breast carcinomas. Additionally, the immunohistochemical and molecular expression results of URG4 were relevant to most prognostic parameters (tumour size, oestrogen and progesterone receptor status, HER2 status and Ki67 proliferative index) for breast cancer. However, unlike the immunohistochemical studies, the molecular studies revealed that there was no significant difference in URG4 expression for different grades of tumour tissues.


The literature data suggest that URG4 overexpression is associated with poor prognosis in many types of cancer. Conversely, our results in breast cancer specimens indicate that URG4 overexpression in breast ductal carcinomas is significantly associated with good prognostic parameters. Nevertheless, these preliminary findings should be confirmed by further studies.


URG4/URGCP Breast cancer mRNA expression Protein expression 



This study was funded by Balıkesir University Coordinator of Scientific Research Projects. The authors would like to appreciate the help from Prof. Dr. Feray Koçkar and Dr. Esra Tokay, for their guidance on the processes in this study.


  1. 1.
    Tufan NL, Lian Z, Liu J, Pan J, Arbuthnot P, Kew M, et al. Hepatitis Bx antigen stimulates expression of a novel cellular gene, URG4, that promotes hepatocellular growth and survival. Neoplasia. 2002;4:355–68.CrossRefGoogle Scholar
  2. 2.
    Li W, Zhou N. URG4 upregulation is associated with tumor growth and poor survival in epithelial ovarian cancer. Arch Gynecol Obstet. 2012;286:209–15.CrossRefGoogle Scholar
  3. 3.
    Song J, Xie H, Lian Z, Yang G, Du R, Zou X, et al. Enhanced cell survival of gastric cancer cells by a novel gene URG4. Neoplasia. 2006;8:995–1002.CrossRefGoogle Scholar
  4. 4.
    Wu M, Chen J, Wang Y, Hu J, Liu C, Feng C, et al. URGCP/URG4 promotes apoptotic resistance in bladder cancer cells by activating NF-κB signalling. Oncotarget. 2015;6:30887–901.Google Scholar
  5. 5.
    Chen LC, Zhang HY, Qin ZY, Wang Y, Mao Y, Yao Y, et al. Serological identification of URGCP as a potential biomarker for glioma. CNS Neurosci Ther. 2014;20:301–7.CrossRefGoogle Scholar
  6. 6.
    Cai J, Li R, Xu X, Zhang L, Wu S, Yang T, et al. URGCP promotes non-small cell lung cancer invasiveness by activating the NF-κB-MMP-9 pathway. Oncotarget. 2015;6:36489–504.Google Scholar
  7. 7.
    Dodurga Y, Eroğlu C, Seçme M, Elmas L, Avcı ÇB, Şatıroğlu-Tufan NL, et al. Anti-proliferative and anti-invasive effects of ferulic acid in TT medullary thyroid cancer cells interacting with URG4/URGCP. Tumour Biol. 2016;37:1933–40.CrossRefGoogle Scholar
  8. 8.
    Dodurga Y, Gundogdu G, Koc T, Yonguç GN, Kucukatay V, Satıroğlu-Tufan NL, et al. Expression of URG4/URGCP, Cyclin D1, Bcl-2, and Bax genes in retinoic acid treated SH-SY5Y human neuroblastoma cells. Contemp Oncol (Pozn). 2013;17:346–9.Google Scholar
  9. 9.
    Dodurga Y, Avcı CB, Susluer SY, Satıroğlu Tufan NL, Gündüz C. The expression of URGCP gene in prostate cancer cell lines: correlation with rapamycin. Mol Biol Rep. 2012;39:10173–7.CrossRefGoogle Scholar
  10. 10.
    Dodurga Y, Oymak Y, Gündüz C, Satıroğlu-Tufan NL, Vergin C, Çetingül N, et al. Leukemogenesis as a new approach to investigate the correlation between up regulated gene 4/upregulator of cell proliferation (URG4/URGCP) and signal transduction genes in leukemia. Mol Biol Rep. 2013;40:3043–8.CrossRefGoogle Scholar
  11. 11.
    Yu G, Meng Q, Zhang T, Zeng C, He B, Zhang S. URG4 expression is a novel prognostic factor for the progression of nasopharyngeal carcinoma and overall survival of patient. Onco Targets Ther. 2016;9:3059–65.CrossRefGoogle Scholar
  12. 12.
    Hong L, Qing O, Ji Z, Chengqu Z, Ying C, Hao C, et al. Downregulation of miR-16 via URGCP pathway contributes to glioma growth. Sci Rep. 2017;7:13470.CrossRefGoogle Scholar
  13. 13.
    Zhang L, Huang H, Zhang L, Hou T, Wu S, Huang Q, et al. URG4 overexpression is correlated with cervical cancer progression and poor prognosis in patients with early-stage cervical cancer. BMC Cancer. 2014;14:885.CrossRefGoogle Scholar
  14. 14.
    Morgensztern D, McLeod HL. PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs. 2005;16:797–803.CrossRefGoogle Scholar
  15. 15.
    Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol. 2006;3:269–80.CrossRefGoogle Scholar
  16. 16.
    Likhite VS, Stossi F, Kim K, Katzenellenbogen BS, Katzenellenbogen JA. Kinase-specific phosphorylation of the estrogen receptor changes receptor interactions with ligand, deoxyribonucleic acid, and coregulators associated with alterations in estrogen and tamoxifen activity. Mol Endocrinol. 2006;20:3120–32.CrossRefGoogle Scholar
  17. 17.
    Lee ER, Kim JY, Kang YJ, Ahn JY, Kim JH, Kim BW, et al. Interplay between PI3K/Akt and MAPK signaling pathways in DNA-damaging drug-induced apoptosis. Biochim Biophys Acta. 2006;1763:958–68.CrossRefGoogle Scholar
  18. 18.
    Liang K, Lu Y, Li X, Zeng X, Glazer RI, Mills GB, et al. Differential roles of phosphoinositide-dependent protein kinase-1 and akt1 expression and phosphorylation in breast cancer cell resistance to Paclitaxel, Doxorubicin, and gemcitabine. Mol Pharmacol. 2006;70:1045–52.CrossRefGoogle Scholar
  19. 19.
    Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene. 2005;24:7455–64.CrossRefGoogle Scholar
  20. 20.
    Knuefermann C, Lu Y, Liu B, Jin W, Liang K, Wu L, et al. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene. 2003;22:3205–12.CrossRefGoogle Scholar
  21. 21.
    Ahmad S, Singh N, Glazer RI. Role of AKT1 in 17beta-estradiol- and insulin-like growth factor I (IGF-I)-dependent proliferation and prevention of apoptosis in MCF-7 breast carcinoma cells. Biochem Pharmacol. 1999;58:425–30.CrossRefGoogle Scholar

Copyright information

© The Japanese Breast Cancer Society 2019

Authors and Affiliations

  1. 1.Department of PathologyBalıkesir University School of MedicineBalıkesirTurkey
  2. 2.Department of Medical BiologyBalıkesir University School of MedicineBalıkesirTurkey

Personalised recommendations